March 6, 2022
1 min read

Pharma sector expected to grow between 6 and 8 % YoY in FY23

The agency said that higher Capex in lieu of the ‘Production-linked Incentives’ (PLI) scheme will restrict the quantum of free cash flow generation during the year….reports Asian Lite News

India’s pharmaceuticals market (IPM) is expected to grow between 6 and 8 per cent on a year-on-year (YoY) basis in FY23.

Accordingly, the growth has been capped due to high base effect and inventory stocking in FY21 on account of Covid-19-led disruption in supplies of key starting materials.

Besides, API (Active Pharmaceuticals Ingredient) businesses are expected to report high single-digit growth in FY23 due to a demand uptick, the overall revenue growth is expected at 9-to-10 per cent YoY.

In a research note, India Ratings and Research (Ind-Ra) said it has maintained a neutral outlook for the Indian pharmaceutical sector for FY23.

The agency said that higher Capex in lieu of the ‘Production-linked Incentives’ (PLI) scheme will restrict the quantum of free cash flow generation during the year.

pharma industry

“Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities,” the note said.

“Cost-cutting measures remain a priority for Indian companies. However, interim disruptions such as high raw material costs and logistic expenses will put pressure on the level of free cash flow generated.”

Besides, the agency said that with the significant improvement in the free cash flow generated in the near term, M&A activities will continue to provide inorganic push in FY23.

“Ind-Ra does not expect the sector’s liquidity to face a major risk, despite similar maturities levels in FY23 and FY24. Large pharma companies generally have large cash balances, which typically account for 14-16 per cent of their revenue.”

Furthermore, most companies have sufficient headroom under debt covenants and diversified funding sources.

“The interest coverage of large pharma players is likely to increase with scale and margin expansion.”

“Ind-Ra expects large pharma companies to continue with their healthy debt-funded capex and research and development programme, given higher visibility in terms of sales growth and profitability.”

ALSO READ: AYYA T1: Russian’s alternative to iPhone

Previous Story

Tesla receives environmental nod to produce EVs at Gigafactory Berlin

Next Story

Melbourne Cricket Ground to be renamed after Shane Warne

Latest from India News

Doval in Moscow Amid US Tariff Threat

During his Moscow visit, NSA Doval will discuss defence ties, the oil issue, and the upcoming Modi-Putin summit..reports Asian Lite news India’s National Security Advisor Ajit Doval is set to meet senior

After Pakistan, China Backing Iran Too?

China and Iran signed a 25-year comprehensive cooperation agreement that covered trade, energy and security, showcasing the strategic value that Beijing places on Tehran….reports Asian Lite News Despite its long-standing claims of

US-India ties is a slow-motion catastrophe

For the first time in two decades, Trump’s actions, statements, and coercive tone have made relations with the US a combustible domestic political issue in India, writes Manoj Menon The post-globalisation uncertainty

Modi Welcomes Marcos Jr to Delhi

PM Modi Welcomes Philippines President Marcos Jr to Strengthen India-Philippines Ties…reports Asian Lite News Prime Minister Narendra Modi on Tuesday warmly welcomed Philippines President Ferdinand R. Marcos Jr at Hyderabad House in

Post-370 Kashmir Reinvents Itself

The developments suggest that Kashmir’s post-abrogation journey is not merely political – it is profoundly social, economic, and cultural….writes Shashikant Trivedi Six years after the abrogation of Article 370, Jammu and Kashmir
Go toTop

Don't Miss

TN police trace stolen Natarajar idol to NY museum

The temple at Thiruvedhikudi Kandiyur is 2,000 years old and

Prestige Masters Series concludes in India

This year’s series saw 650 golfers compete over four qualifying